Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Search Results

Filter
  • 1-10 of  36,629 results for ""Antibodies, Monoclonal, Humanized""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Re-Engineering Therapeutic Anti-Aβ Monoclonal Antibody to Target Amyloid Light Chain.

  • Authors : Bai J; Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.; Li X

Subjects: Alzheimer Disease*/Alzheimer Disease*/Alzheimer Disease*/metabolism ; Alzheimer Disease*/Alzheimer Disease*/Alzheimer Disease*/therapy ; Amyloidosis*/Amyloidosis*/Amyloidosis*/therapy

  • Source: International journal of molecular sciences [Int J Mol Sci] 2024 Jan 27; Vol. 25 (3). Date of Electronic Publication: 2024 Jan 27.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

Record details

×
Academic Journal

Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.

  • Authors : Sriphoosanaphan S; Department of Medicine, Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.; Pantumongkol W

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Liver Neoplasms*/Liver Neoplasms*/Liver Neoplasms*/drug therapy ; Antibodies, Monoclonal, Humanized*

  • Source: PloS one [PLoS One] 2024 Mar 21; Vol. 19 (3), pp. e0300327. Date of Electronic Publication: 2024 Mar 21 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience.

  • Authors : Qiu L; Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China.; Ma L

Subjects: Arthritis, Juvenile*/Arthritis, Juvenile*/Arthritis, Juvenile*/drug therapy ; Antibodies, Monoclonal, Humanized*; Child

  • Source: Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2024 Mar 19; Vol. 22 (1), pp. 38. Date of Electronic Publication: 2024 Mar 19.Publisher: BioMed Central Country of Publication: England NLM ID: 101248897 Publication Model: Electronic Cited Medium: Internet ISSN: 1546-0096

Record details

×
Academic Journal

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.

Subjects: Respiratory Syncytial Virus Vaccines* ; Respiratory Syncytial Virus, Human* ; Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/epidemiology

  • Source: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2024 Mar 07; Vol. 73 (9), pp. 209-214. Date of Electronic Publication: 2024 Mar 07.Publisher: U.S. Centers for Disease Control Country of Publication: United States NLM ID: 7802429 Publication Model: Electronic Cited Medium: Internet

Record details

×
Academic Journal

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.

  • Authors : Liu Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.; Ping L

Subjects: Hodgkin Disease*/Hodgkin Disease*/Hodgkin Disease*/drug therapy ; Hodgkin Disease*/Hodgkin Disease*/Hodgkin Disease*/etiology ; Hodgkin Disease*/Hodgkin Disease*/Hodgkin Disease*/pathology

  • Source: BMC medicine [BMC Med] 2024 Mar 07; Vol. 22 (1), pp. 107. Date of Electronic Publication: 2024 Mar 07.Publisher: BioMed Central Country of Publication: England NLM ID: 101190723 Publication Model: Electronic Cited Medium: Internet ISSN: 1741-7015

Record details

×
Academic Journal

Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge.

  • Authors : Chesdachai S; Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. .; Rivera CG

Subjects: Outpatients* ; COVID-19* ; Antibodies, Neutralizing*

  • Source: Scientific reports [Sci Rep] 2024 Mar 05; Vol. 14 (1), pp. 5430. Date of Electronic Publication: 2024 Mar 05.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.

  • Authors : Chen Q; College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.; Sun Q

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Liver Neoplasms*/Liver Neoplasms*/Liver Neoplasms*/drug therapy ; Antibodies, Monoclonal, Humanized*

  • Source: PloS one [PLoS One] 2024 Mar 04; Vol. 19 (3), pp. e0295090. Date of Electronic Publication: 2024 Mar 04 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.

  • Authors : Kinami T; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.; Uchikawa S

Subjects: Carcinoma, Hepatocellular* ; Liver Neoplasms* ; Hypertension, Portal*

  • Source: Cancer medicine [Cancer Med] 2024 Mar; Vol. 13 (5), pp. e7025.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma.

  • Authors : Chao L; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.; Liu J

Subjects: Esophageal Squamous Cell Carcinoma*/Esophageal Squamous Cell Carcinoma*/Esophageal Squamous Cell Carcinoma*/drug therapy ; Esophageal Squamous Cell Carcinoma*/Esophageal Squamous Cell Carcinoma*/Esophageal Squamous Cell Carcinoma*/surgery ; Esophageal Neoplasms*/Esophageal Neoplasms*/Esophageal Neoplasms*/drug therapy

  • Source: Thoracic cancer [Thorac Cancer] 2024 Mar; Vol. 15 (8), pp. 622-629. Date of Electronic Publication: 2024 Feb 05.Publisher: Wiley Publishing Asia Pty Ltd Country of Publication: Singapore NLM ID: 101531441 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Scleritis following intravitreal brolucizumab injection: a case series.

  • Authors : Takayama T; Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-Shi, Tochigi, 329-0431, Japan.; Inoda S

Subjects: Scleritis*/Scleritis*/Scleritis*/chemically induced ; Scleritis*/Scleritis*/Scleritis*/drug therapy ; Scleritis*/Scleritis*/Scleritis*/diagnosis

  • Source: Journal of medical case reports [J Med Case Rep] 2024 Feb 29; Vol. 18 (1), pp. 80. Date of Electronic Publication: 2024 Feb 29.Publisher: BioMed Central Country of Publication: England NLM ID: 101293382 Publication Model: Electronic Cited Medium: Internet ISSN: 1752-1947

Record details

×
  • 1-10 of  36,629 results for ""Antibodies, Monoclonal, Humanized""